A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis.
Atopic dermatitis, or eczema, causes the skin to become dry, itchy, red, and sore. In healthy skin, the outer layer acts like a protective shield, keeping moisture in and irritants out. In eczema, this barrier does not work as well. This early research study looks at an experimental treatment called TRIV-509. The main goal is to test how safe it is and how well it helps repair the skin barrier in adults living with eczema. Because this is an early Phase 1 trial, doctors will closely check how the body handles the treatment and monitor any side effects. Taking part helps researchers learn whether TRIV-509 could become a useful new option for eczema care in the future. Qualified medical staff will support volunteers throughout the study.
At a glance
What is this study about?
Atopic dermatitis is the most common form of eczema. People with this condition experience patches of dry, inflamed, and intensely itchy skin. A key reason this happens is a problem with the skin barrier. Think of healthy skin like a sturdy brick wall: it keeps hydration inside and blocks germs, allergens, and irritants. In eczema, this wall has gaps, allowing moisture to escape and irritants to get in, leading to flare-ups.
This trial is looking at an investigational treatment named TRIV-509. The researchers want to discover whether TRIV-509 can help strengthen or heal this outer skin layer. By understanding how the treatment affects skin barrier function, scientists hope to find new ways to reduce eczema symptoms and prevent future flare-ups.
Because this is an early-stage clinical study (Phase 1), safety is the top priority. Doctors will closely watch how volunteers respond to TRIV-509, measuring changes in their skin and checking for any unexpected reactions. The results will help decide if the treatment should move on to larger studies in more patients.
Key takeaways
- Testing a new treatment called TRIV-509 for atopic dermatitis (eczema).
- Focuses on safety and how well the treatment helps rebuild the skin barrier.
- Open to adults aged 18 and older with eczema.
- Early-stage clinical trial (Phase 1) with close medical supervision.
- Participation is entirely voluntary, and you can leave at any time.
Who may be eligible?
This trial is open to adults aged 18 and older who have a diagnosis of atopic dermatitis (eczema). Both men and women can take part.
To join, participants must have active eczema patches that can be assessed by the study team. You may need to meet certain health criteria, such as not having other serious skin conditions or general health issues that could interfere with the study tests.
Because this is an early research trial, you may be asked to pause certain eczema creams or other treatments for a short time before and during the study. The research team will discuss these rules with you in detail to make sure taking part is safe for your health.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You have been diagnosed with atopic dermatitis (eczema).
- You currently have active areas of eczema on your skin.
- You are willing to attend scheduled clinic visits for tests and monitoring.
- You are comfortable temporarily adjusting certain skin treatments if required by the study.
What does participation involve?
Taking part will involve visiting a specialised clinical research clinic. Before starting, the study team will explain everything and ask you to sign a consent form. During your visits, doctors and nurses will examine your skin, check your overall health, and take routine measurements such as blood pressure and small blood or skin swab samples. You will receive the study treatment, TRIV-509, as directed by the clinic staff. Researchers will use gentle, non-invasive tests to measure how well your skin holds moisture. The total time in the study will include regular check-ups and follow-up appointments over several weeks or months to monitor your skin and ensure your safety.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is TRIV-509?
TRIV-509 is an experimental treatment being researched to see if it can repair and strengthen the skin barrier in people with atopic dermatitis.
What is a Phase 1 study?
A Phase 1 study is one of the earliest stages of testing in humans. It focuses mainly on checking safety, finding the right dose, and seeing how the body reacts to the treatment.
Will I have to pay to take part?
No, you do not have to pay for the study treatment or tests. Clinical trials often help cover reasonable travel expenses as well.
Can I keep using my normal eczema creams?
You may need to avoid certain creams or moisturisers on test areas of your skin for a short time so researchers can get accurate results. The trial doctor will explain what is allowed.
What happens if I change my mind after joining?
You are free to stop participating at any time. Leaving the trial will never affect your relationship with your regular doctor or your usual NHS care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.